Published in Cancer Weekly, April 23rd, 2002
That is the belief of researchers at the University of Louisville in Kentucky, who have spent time investigating the chemosensitization properties of transcription factor E2F-1 gene therapy in melanomas treated with standard chemotherapy. In an earlier study, the investigators demonstrated that E2F-1 gene therapy stimulates apoptosis in melanoma cells. Their current research, reported in the journal of Cancer Research, builds on those earlier efforts.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.